Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Polina Bukshpun
- Phone Number: +1-818-536-2358
- Email: polina.bukshpun@evommune.com
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 5K3
- Dandelion Allergy Centre
-
Niagara Falls, Ontario, Canada, L2H 1H5
- Allergy Research Canada
-
Ottawa, Ontario, Canada, K1H 1E4
- Red Maple Trials
-
-
Quebec
-
Montreal, Quebec, Canada, H1Y 3L1
- Centre de Recherche Saint-Louis - Montréal
-
Québec, Quebec, Canada, G1W 4R4
- Centre de Recherche Saint-Louis
-
-
-
-
Osaka
-
Sakai, Osaka, Japan, 5938324
- Dermatology and Ophthalmology Kume Clinic
-
Takatsuki, Osaka, Japan, 5690824
- Yoshikawa Skin Clinic
-
Takatsuki, Osaka, Japan, 5698686
- Osaka Medical and Pharmaceutical University Hospital
-
-
Tokyo
-
Minato-Ku, Tokyo, Japan, 1080014
- Mita Dermatology
-
Shinagawa-Ku, Tokyo, Japan, 1416003
- ThinkPark Dermatology Clinic
-
Tachikawa, Tokyo, Japan, 1900023
- Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
-
Toshima-ku, Tokyo, Japan, 1710021
- Ikebukuro Nishiguchi Fukurou Dermatology
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35244
- Cahaba Dermatology Skin Health Center
-
Mobile, Alabama, United States, 36608
- Velocity Clinical Research, Mobile
-
-
California
-
Fremont, California, United States, 94538
- Center for Dermatology Clinical Research
-
Lancaster, California, United States, 93534
- Antelope Valley Clinical Trials
-
Northridge, California, United States, 91325
- Northridge Clinical Trials
-
Santa Rosa, California, United States, 95405
- NorthBay Clinical Research
-
Upland, California, United States, 91786
- Integrated Research of Inland
-
Ventura, California, United States, 93003
- Fomat Medical Research
-
-
Florida
-
Fort Myers, Florida, United States, 33912
- AMR Fort Myers
-
Tampa, Florida, United States, 33607
- Advanced Clinical Research Institute
-
-
Illinois
-
Normal, Illinois, United States, 61761
- Sneeze, Wheeze & Itch Associates LLC
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- The Indiana Clinical Trials Center
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- The Iowa Clinic
-
-
Kansas
-
Hutchinson, Kansas, United States, 67502
- Hutchinson Clinic
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Bluegrass Allergy Care
-
Louisville, Kentucky, United States, 40205
- Delricht Research Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Delricht Research Louisiana
-
Lafayette, Louisiana, United States, 70508
- Velocity Clinical Research, Lafayette
-
New Orleans, Louisiana, United States, 70115
- DelRicht Research
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Boston Specialists
-
-
Michigan
-
Northville, Michigan, United States, 48167
- MI Skin Innovations
-
-
Missouri
-
Wildwood, Missouri, United States, 63040
- DelRicht Research - Town Center Dermatology
-
-
New York
-
Woodbury, New York, United States, 11797
- Vitality Clinical Trials
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Allergy Partners Clinical Research
-
Charlotte, North Carolina, United States, 28205
- Delricht Research - Priority Care
-
Statesville, North Carolina, United States, 28625
- Piedmont Healthcare
-
-
Ohio
-
Boardman, Ohio, United States, 44512
- Optima Research Boardman
-
Canal Winchester, Ohio, United States, 43110
- DOCS Dermatology Research
-
Cincinnati, Ohio, United States, 45236
- Bernstein Clinical Research Center
-
Toledo, Ohio, United States, 43617
- Toledo Institute of Clinical Research
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- AMR Myrtle Beach
-
North Charleston, South Carolina, United States, 29420
- National Allergy and Asthma Research
-
-
Tennessee
-
Smyrna, Tennessee, United States, 37167
- Delricht Research Smyrna
-
-
Texas
-
Austin, Texas, United States, 78726
- Austin Regional Clinic ARC Clinical Research
-
Cypress, Texas, United States, 77429
- Studies in Dermatology
-
El Paso, Texas, United States, 79912
- Western Sky Medical Research
-
Prosper, Texas, United States, 75078
- Delricht Research - Lockhard Matter Dermatology
-
-
Utah
-
Layton, Utah, United States, 84041
- AMR Utah
-
-
Washington
-
Seattle, Washington, United States, 98104
- Seattle Clinical Research Center
-
-
Wisconsin
-
Greenfield, Wisconsin, United States, 53228
- Allergy, Asthma, and Sinus Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed CSU diagnosis for at least 3 months with an inadequate response to H1-antihistamines.
- Subjects who are taking H1-antihistamines must be on a stable regimen 4 weeks prior to Day 1 and while on study.
- Urticaria Activity Score (UAS7) equal to or greater than 16 at Day 1. UAS entries must be completed for a minimum of 4 out of the 7 days prior to Day 1.
Exclusion Criteria:
- Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening, according to the Investigator's discretion.
- Use of certain medications.
- History of diseases with urticaria or angioedema symptoms, other than CSU and symptomatic dermographism.
- Significant medical history other than CSU, or any other condition which might interfere with the evaluation of CSU.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose 1
Orally administered EVO756, dose 1
|
Dose 1
Dose 2
Dose 3
|
|
Experimental: Dose 2
Orally administered EVO756, dose 2
|
Dose 1
Dose 2
Dose 3
|
|
Experimental: Dose 3
Orally administered EVO756, dose 3
|
Dose 1
Dose 2
Dose 3
|
|
Placebo Comparator: Placebo control
Orally administered placebo control
|
Placebo control
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mean change from baseline in UAS7
Time Frame: Week 12
|
Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change from baseline in UAS7
Time Frame: Week 12
|
Week 12
|
|
Mean and percent change from baseline in UAS7
Time Frame: Weeks 1, 2, 4, 8
|
Weeks 1, 2, 4, 8
|
|
Mean and percent change from baseline in ISS7
Time Frame: Weeks 1, 2, 4, 8, 12
|
Weeks 1, 2, 4, 8, 12
|
|
Mean and percent change from baseline in HSS7
Time Frame: Weeks 1, 2, 4, 8, 12
|
Weeks 1, 2, 4, 8, 12
|
|
Mean and percent change from baseline in AAS7
Time Frame: Weeks 1, 2, 4, 8, 12
|
Weeks 1, 2, 4, 8, 12
|
|
Proportion of subjects achieving UAS7 ≤ 6
Time Frame: Weeks 1, 2, 4, 8, 12
|
Weeks 1, 2, 4, 8, 12
|
|
Proportion of subjects achieving UAS7 = 0
Time Frame: Weeks 1, 2, 4, 8, 12
|
Weeks 1, 2, 4, 8, 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Hypersensitivity, Immediate
- Hypersensitivity
- Skin Diseases
- Skin Diseases, Vascular
- Pathological Conditions, Signs and Symptoms
- Skin and Connective Tissue Diseases
- Chronic Urticaria
- Urticaria
- Substandard Drugs
- Pharmaceutical Preparations
- Counterfeit Drugs
Other Study ID Numbers
Other Study ID Numbers
- EVO756-CSU001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.